James J. Loughlin, Director at Edge Therapeutics, Inc. (EDGE), bought 3,000 shares at $7.63 ($23K) on 2016-03-11, disclosed to the SEC on 2016-03-15.
Open-market purchase of $23k EDGE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.58 | 100 | $758 | 3.3% |
| 2 | $7.63 | 180 | $1K | 6.0% |
| 3 | $7.63 | 13 | $99 | 0.4% |
| 4 | $7.63 | 500 | $4K | 16.7% |
| 5 | $7.64 | 500 | $4K | 16.7% |
| 6 | $7.64 | 600 |
| $5K |
| 20.0% |
| 7 | $7.64 | 1,107 | $8K | 36.9% |
| Total | $7.64 avg | 3,000 | $23K | 100% |
| Filing → |
| CELG | SELL | 2018-03-13 | $1.7M | — | Filing → |
| CELG | SELL | 2017-06-27 | $2.5M | — | Filing → |
| CELG | SELL | 2017-05-02 | $1.1M | — | Filing → |